Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon May 15, 2023 2:16pm
194 Views
Post# 35448726

RE:What's Next?

RE:What's Next?
Eoganacht wrote:
Given the stability of CRs after the 180 day assessment, and taking into account only patients who were CR at both their 90 day and 180 day assessments I think we can be confident that:
 
90 days from now we should be at a 450 day CR rate of 31%
(12 out of 39 should be CR)
 
180 days from now we should be at a 450 day CR rate of 34%
(14 out of 41 should be CR)
 
270 days from now we should be at a 450 day CR rate of 40%
(19 out of 47 should be CR)
 
Stellar results. And this includes the 12 undertreated patients.

Nice Eoganacht.  Without 12 undertreated patients we would may e be looking at 50-55% 450 CR rate Imo. With only 2 treatments. I can imagine that NR and IR patients will eventually be given 3-4 treatments and perhaps we get another 10-20 % increase in CR rate perhaps? 

<< Previous
Bullboard Posts
Next >>